$MMSI

Merit Medical Systems (MMSI) reported Q2 2026 sales of $418.84 million and net income of $38.8 million, and raised its full-year 2026 revenue outlook to $1.63 billion to $1.64 billion, according to the company. The article notes ongoing product recalls and reimbursement risks and mentions a 2029 narrative of about $1.8 billion revenue and $213.7 million earnings.

Merit Medical Systems (MMSI) reported Q2 2026 revenue of $418.8 million, up 10% GAAP, and non-GAAP EPS of $1.19. Non-GAAP operating margin was 22.6% and free cash flow $51.9 million. The company raised 2026 revenue guidance to $1.631B-$1.643B and non-GAAP EPS to $4.25-$4.35, and guided Q3 revenue to $408M-$413M.

Merit Medical Systems (MMSI) reported Q2 2026 revenue of $418.8 million, up 10% GAAP, and non-GAAP EPS of $1.19. Non-GAAP operating margin was 22.6% and free cash flow $51.9 million. The company raised 2026 revenue guidance to $1.631B-$1.643B and non-GAAP EPS to $4.25-$4.35, and guided Q3 revenue to $408M-$413M.

Peterson Neil W. (CHIEF OPERATING OFFICER) sold 21,449 shares of MERIT MEDICAL SYSTEMS INC (MMSI) at $85.00 ($1.82M total) on 2026-08-04.

Merit Medical Systems reported Q2 revenue of $418.8M, above analysts’ $405.3M estimate, and adjusted EPS of $1.19 versus $0.96. The company slightly raised full-year revenue guidance to $1.64B and adjusted EPS to $4.30 at the midpoint. Management cited Biolife and C2 integration, oncology launches (OneMark, SCOUT MD), and margin gains.

Merit Medical Systems Inc (NASDAQ:MMSI) posted better-than-expected earnings for the second quarter on Thursday. The company posted adjusted EPS of $1.19, beating market estimates of 96 cents per share. The company’s sales came in at $418.843 million versus expectations of $405.268 million. Merit Medical Systems raised its FY2026 adjusted EPS guidance from $4.01-$4.15 to $4.25-$4.35 and increased its sales forecast from $1.612 billion-$1.634 billion to $1.631 billion-$1.643 billion.

Medical device company Merit Medical Systems (NASDAQ: MMSI) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 9.5% year on year to $418.8 million. The company’s full-year revenue guidance of $1.64 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.19 per share was 24% above analysts’ consensus estimates. Is now the time to buy Merit Medical Systems? Find out by accessing our full research report, it’s free.

MERIT MEDICAL SYSTEMS INC (MMSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mmsi-20260730xex99d1.htm EX-99.1 Exhibit 99.1 ​ ​ ​ ​ ​ ​ ​ ​ Contacts: ​ ​ ​ ​ PR/Media Inquiries: Sarah Comstock Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC ICR Healthcare ​ ​ +1-801-432-2864 +1-443-213-0509 ​ ​ sarah.comstock@merit.com mike.piccinino@i

Merit Medical Systems (NASDAQ: MMSI) is set to report Q2 earnings Thursday after the bell. The company previously reported $381.9 million revenue, up 7.5% year over year, and beat EPS and full-year EPS guidance. For the upcoming quarter, analysts expect revenue growth of about 6% y/y. MMSI has an average analyst price target of $90.09 versus $78.29.

Merit Medical Systems (NASDAQ: MMSI) said it will report second-quarter 2026 results for the quarter ended June 30, 2026 after the market close on July 30, 2026. The company will host an investor conference call that day at 4:30 p.m. ET, with a live webcast and slide deck available on its website.